Comparative Pharmacology
Head-to-head clinical analysis: CERETEC versus CIS MDP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CERETEC versus CIS MDP.
CERETEC vs CIS-MDP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Technetium-99m exametazime (Ceretec) is a lipophilic radiopharmaceutical that crosses the blood-brain barrier and is taken up by brain tissue in proportion to regional cerebral blood flow. Once inside cells, it undergoes intracellular conversion to a hydrophilic form, trapping it in the brain and allowing SPECT imaging.
CIS-MDP (cisplatin) is a platinum-containing antineoplastic agent that forms intrastrand and interstrand DNA crosslinks, inhibiting DNA replication and transcription through binding to purine bases.
555-740 MBq (15-20 mCi) intravenously as a single dose for SPECT imaging.
20 mCi (740 MBq) intravenous injection for bone scintigraphy; imaging performed 2-4 hours post-injection.
None Documented
None Documented
Terminal: 6 hours (range 4–8 h); clinical: supports twice-daily dosing in nuclear medicine studies.
Terminal elimination half-life: 6-8 hours; clinically relevant for imaging timing and clearance from blood pool.
Renal: 40% unchanged; biliary/fecal: 60% (as metabolites and parent compound).
Renal: 85-95% of administered dose excreted unchanged in urine within 24 hours; biliary/fecal: <5% eliminated via feces.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical